Eris Lifesciences schedules 20th AGM for September 25, 2026
- Eris Lifesciences schedules 20th AGM for September 25, 2026
- Mr. Sujesh Vasudevan seeks re-appointment as Independent Director
- Mr. Kaushal Kamlesh Shah offers himself for re-appointment as Director
- Cost Auditor remuneration of ₹3,66,000 awaits ratification
*this image is generated using AI for illustrative purposes only.
Eris Lifesciences has scheduled its 20th Annual General Meeting (AGM) for September 25, 2026, at 11:00 am. The meeting will be conducted via video conferencing.
The Board approved the agenda during its meeting on August 31, 2026. Shareholders will vote on ordinary and special business items, including director re-appointments and auditor remuneration.
Key Agenda Items
The AGM notice outlines specific resolutions for shareholder approval. Mr. Kaushal Kamlesh Shah retires by rotation and offers himself for re-appointment as a Director. He currently serves as Whole-time Director.
Mr. Sujesh Vasudevan seeks re-appointment as an Independent Director for a second five-year term. His new tenure is set to commence on July 25, 2027, and run until July 24, 2032. This follows his initial appointment in July 2022.
The Board also seeks ratification of the remuneration for Cost Auditors. M/s. Kiran J Mehta & Co. has been appointed to audit cost records for FY27. The proposed remuneration is ₹3,66,000.
Meeting Logistics
The company will conduct the AGM through Video Conferencing (VC) in compliance with Ministry of Corporate Affairs circulars. Members can participate remotely using the InstaMeet facility provided by MUFG Intime India Private Limited.
Remote e-voting will be available from September 22, 2026, at 9:00 am until September 24, 2026, at 5:00 pm. The cut-off date for voting eligibility is September 18, 2026. Results are expected by September 29, 2026.
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.75% | -4.23% | -3.84% | -0.76% | -20.65% | 0.0% |
How might the re-appointment of Mr. Kaushal Kamlesh Shah influence Eris Lifesciences' strategic direction for generic drug expansion?
What impact could the extended tenure of Independent Director Mr. Sujesh Vasudevan have on corporate governance and board oversight until 2032?
Does the approved remuneration for Cost Auditors signal any anticipated changes in cost accounting standards or regulatory scrutiny for FY27?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
